ClinicalTrials.gg
RecruitingNCT06301412COTTIS-2Updated Jan 6, 2025

Combination of Hypothermia and Thrombectomy in Acute Stroke

A Phase 3 interventional study of hypothermia in Ischemic Stroke, Large Vessel Occlusion and Endovascular Treatment, sponsored by University of Freiburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by University of Freiburg · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.

Planned enrollment
39th of 101
400 · median 223
Started
2024
with 6 others
Phase 3
20 of 164
3 open now
Primary completion
2026-03
later than 13 of 49 live
Registered
142nd of 164
by date

Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 39th largest by planned enrollment of the 101 interventional ones that give a count, is one of 7 that started in 2024, is one of 20 in phase 3, reaches primary completion later than 13 of the 49 other live ones, and was the 142nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Ischemic Stroke with a site in Germany, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion.

The main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed.

Researchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.

Read the detailed description

Despite the well-established benefit of endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion (LVO), more than half of patients treated with EVT remain functionally dependent despite high reperfusion rates. Thus, new strategies such as additional neuroprotection using hypothermia need to be explored, first to bridge time to reperfusion and second, to attenuate reperfusion injury.

Although therapeutic hypothermia has consistently demonstrated robust neuroprotection in animal ischemic-reperfusion models, randomized trials in acute stroke patients have failed to demonstrate the efficacy of induced hypothermia. The reasons for this treatment failure are diverse and include treatment delay, the unfeasibility of inducing and maintaining hypothermia due to intolerance and shivering in awake patients, the missing recanalization in a large proportion of patients, the heterogeneity of patients included, and too deep (32-34°C) hypothermia associated with an increase in side effects.

In the pilot study COTTIS-1, we could demonstrate the feasibility and safety of immediately induced intraischemic hypothermia to 35°C with non-invasive transnasal cooling by RhinoChill® (BrainCool) followed by surface cooling for 6h after recanalization in sedated and intubated patients with LVO undergoing EVT. By combining this cooling technique with thrombectomy we have tried to address the above mentioned reasons for hypothermia failure. In COTTIS-1, the target temperature of 35°C was reached within 30 min, corresponding to a cooling rate of 2.6°C/h. All patients reached the target temperature, and 86% of the patients had reached ≤35°C at recanalization by thrombectomy. 68% of patients had a good outcome (independency) after 3 months. There were only asymptomatic side effects during hypothermia.

As a consequence, the present COTTIS-2 study is planned to evaluate the efficiency of this cooling protocol in a multicentric, randomized, controlled, end-point-blinded study in Germany.

03

Conditions studied

  • Ischemic Stroke
  • Large Vessel Occlusion
  • Endovascular Treatment

Keywords

  • hypothermia
  • neuroprotection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-stroke modified Rankin Scale (mRS) 0-2 [7-point scale rating from 0 (no symptoms) to 6 (dead)]
  • Acute ischemic stroke with NIHSS >5
  • Intracranial occlusion of the M1 or M2 segment of the middle cerebral artery (MCA) or internal carotid artery (ICA) or tandem occlusion on CT-angiography or MR-angiography with indication for endovascular treatment:
  • Time window 0-24h:

    1. Last seen normal to groin puncture \< 6h: native CT or MRI-DWI with ASPECTS >5
    2. Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial

      • Infarct core \<70ml (DWI oder CBF\<30%)
      • Penumbra > 15ml (Tmax >6sec)
      • Ratio penumbra/core >1.8
  • with or without iv thrombolysis with rtPA

Exclusion criteria

Exclusion Criteria:

  • Patients with an intranasal obstruction that prevents complete insertion of the nasal cannula should not be treated with the RhinoChill system.
  • Known severe hemorrhagic diathesis ( (INR) >3.0, partial thromboplastin time (PTT) > 70s, count \< 50.000/μl)
  • Brain trauma or neurovascular surgery/intervention \<3 months
  • Severe infection
  • Pregnant women or women of (women of childbearing potential with negative pregnancy test may be included)
  • Known cerebral vasculitis
  • Proof of bleeding in cerebral CT or MRI (cerebral microbleeds in MRI [hypertensive or in the context of cerebral amyloid angiopathy] is permitted).
  • Known \< 6 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • No intervention
    EVT group

    standard endovascular treatment (EVT) for large vessel occlusion (LVO) without hypothermia

  • Active comparator
    EVT group plus hypothermia group

    standard endovascular treatment (EVT) for large vessel occlusion (LVO) combined with hypothermia

    Device: hypothermia

Interventions

  • Devicehypothermia

    hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C

06

What researchers measure

Primary outcomes

  1. functional outcome

    The presence of patients with good neurological outcome after 3 months as defined by modified Rankin Scale (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death) of 0-2 or back to baseline before stroke

    Time frame: 3 months

Secondary outcomes

  1. infarction volume

    Infarction volume assessed in the standard CT 24 hours after thrombectomy

    Time frame: 24 hours

  2. increase in infarction

    increase of the infarct core based on imaging at the time of admission (DWI-MRI or CBF\<30% of contralateral side at CT-Perfusion) and CT after 24 hours

    Time frame: 24 hours

  3. recanalization result

    Recanalization result (by mTICI score: successful recanalization mTICI 2b-3) after thrombectomy (based on angiography during/after thrombectomy) and 24 hours after thrombectomy (based on ultrasound of the cerebral vessels)

    Time frame: after thrombectomy and 24 hours

  4. neurological improvement

    Change of at least 8 points on the National Institutes of Health Stroke Scale (NIHSS; on which scores range from 0 to 42, with higher scores indicating a greater deficit) at 48 hours after thrombectomy

    Time frame: 48 hours

  5. outcome at discharge

    modified Rankin Score (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death) upon discharge/transfer in rehabilitation

    Time frame: up to 3 months

  6. shift in functional outcome

    ordinal shift across the range of modified Rankin Score (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death)

    Time frame: 3 months

  7. very good clinical outcome

    Presence of patients with very good clinical outcome after 3 months (mRS 0-1)

    Time frame: 3 months

  8. mortality

    Mortality during acute hospitalisation and after 3 months

    Time frame: 3 months

  9. Length of ventilation

    Length of mechanical ventilation

    Time frame: 3 months

  10. Length of stay

    Length of ICU stay and hospital stay

    Time frame: 3 months

  11. body temperature

    Temperature at admission, at recanalization, and first 6 hours after recanalization, and at 24 hours

    Time frame: 24 hours

  12. time to groin puncture

    Time from arrival until groin puncture

    Time frame: baseline, pre-intervention

  13. time to recanalization

    Time from arrival until recanalization

    Time frame: periprocedurally

Other outcomes

  1. Occurrence of intracerebral haemorrhage (ICH)

    * Any ICH (subarachnoid, intraparenchymal, intraventricular) on the CT after 24 hours * Symptomatic ICH (defined according to SITS-MOST criteria): Hematoma \>30% of initial infarction volume associated with a clinical deterioration in NIHSS score of at least 4 points within 24 hours after thrombectomy

    Time frame: 24 hours

  2. Complications associated with hypothermia

    * Nosebleed and pailing of the nose * Periorbital emphysema * Pneumocephalus (in 24-hour control CT) * Blood pressure, heart rate, oxygen saturation SO2 * Episodes with severe hypotension with systolic blood pressure \<110mmHg * Incidence of pneumonia (defined as: any new pulmonary infiltrate on radiographic imaging occurring \<48hrs after admission combined with at least one of the subsequent findings: fever \>38°C, leukopenia/leucocytosis, purulent secretions with positive cultures) * Disturbances in electrolytes, renal function, coagulation (potassium, sodium, chloride, creatinine, INR, pTT, thrombocytes measured on admission before hypothermia and at 24 hours)

    Time frame: 24hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual patient data (after anonymization), on which the results of the present study are based, can be made available to scientists upon request (methodologically meaningful evaluation proposal approved by a committee specifically appointed for this evaluation proposal) (6 months to 36 months after publication of the study)

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: 6 months to 36 months after publication of the study

Access criteria: upon request of scientists with methodologically meaningful evaluation proposal approved by a committee specifically appointed for this evaluation proposal

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2026, 20 months after the start.

Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 20 months is below that.

Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Mar 8, 2024
StartActual
Jul 7, 2024
Primary completionEst.
Mar 18, 2026
CompletionEst.
Jun 18, 2026
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06301412
Lead sponsor
University of Freiburg
Collaborators
European Union, E+E CRO consulting, Vienna, Austria, Center for Medical data science, University of Vienna, Austria
Responsible party
Juergen Bardutzky (Prof. Dr. med. Juergen Bardutzky, University of Freiburg) — Principal investigator
First posted
Mar 8, 2024
Start date
Jul 7, 2024
Primary completion
Mar 18, 2026 (estimated)
Completion
Jun 18, 2026 (estimated)
Last update
Jan 6, 2025

Study contacts

Juergen Bardutzky, Prof.
Contact
juergen.bardutzky@uniklinik-freiburg.de
+49-15237729739
Wolf-Dirk Niesen, PD Dr.
Contact
wolf-dirk.niesen@uniklinik-freiburg.de
0049-761-270-53050
Juergen Bardutzky, Prof.
principal investigator · University of Freiburg, Department of Neurology, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion